missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD55/DAF Antibody (F4-29D9), Allophycocyanin/Cy7, Novus Biologicals™
Mouse Monoclonal Antibody
Brand: Novus Biologicals NBP2-47963APCCY7
This item is not returnable.
View return policy
Description
CD55/DAF Monoclonal specifically detects CD55/DAF in Human samples. It is validated for Flow Cytometry.
Specifications
| CD55/DAF | |
| Monoclonal | |
| APC-Cyanine7 | |
| PBS with 0.05% Sodium Azide | |
| CD55 | |
| Human umbilical vein endothelial cells (HUVEC) | |
| 0.1 mL | |
| Primary | |
| Recognizes a single chain glycoprotein of 70kDa, identified as CD55. This monoclonal antibody was clustered in Kobe at the Sixth International Workshop on Human Leukocyte Differentiation Antigens as F429D-9 (N-L120). CD55/DAF is widely expressed on cells throughout the body including leukocytes, erythrocytes, epithelium, endothelium, and fibroblasts. It is a Glycosyl phosphatidylinositol anchored (GPI-anchored) member of the membrane bound complement regulatory proteins that inhibit autologous complement cascade activation. It prevents the amplification steps of the complement cascade by interfering with the assembly of the C3-convertases, C4b2a and C3bBb, and the C5-convertase, C4b2a3b and C3bBb3b. CD55 also serves as receptor for CD97 and for echovirus and Coxsackie B virus. Anti-CD55 can be used as marker for paroxysmal nocturnal hemoglobinuria (PNH). | |
| Store at 4°C in the dark. Do not freeze. |
| Flow Cytometry | |
| F4-29D9 | |
| Flow Cytometry | |
| CD55 antigen, CD55 molecule, decay accelerating factor for complement (Cromer blood group), CRdecay accelerating factor for complement (CD55, Cromer blood group system), CROMDAFcomplement decay-accelerating factor, decay accelerating factor for complement, TC | |
| Mouse | |
| Protein A or G purified | |
| Immunology | |
| 1604.0 | |
| Human | |
| IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction